The company plans to initiate Phase 3 development with the subcutaneous formulation of VK2735 in the first half of 2025. About GLP-1 and Dual GLP-1/GIP Agonists Activation of the glucagon-like ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment ...

The rapid enrolment in the study suggests strong demand and interest in VK2735. This aligns with ... CT-996 and CT-868. A dual GLP-1/GIP receptor agonist, CT-388, is being evaluated in a mid ...

The study initiation is supported by data from an early-stage study, which showed that patients who received oral VK2735 lost up ... CT-996 and CT-868. A dual GLP-1/GIP receptor agonist, CT ...

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing ...

"As with our previous Phase 2 study of subcutaneous VK2735, interest in participating in the Phase 2 VENTURE-Oral study was high and drove an efficient rate of enrollment," said Brian Lian ...

The Phase 2 VENTURE-Oral Dosing Trial is a randomized, double-blind, placebo-controlled multicenter study designed to evaluate the safety, tolerability, pharmacokinetics and weight loss efficacy of ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...